Addressing the heterogeneity in liver diseases using biological networks

Abstract The abnormalities in human metabolism have been implicated in the progression of several complex human diseases, including certain cancers. Hence, deciphering the underlying molecular mechanisms associated with metabolic reprogramming in a disease state can greatly assist in elucidating the disease aetiology. An invaluable tool for establishing connections between global metabolic reprogramming and disease development is the genome-scale metabolic model (GEM). Here, we review recent work on the reconstruction of cell/tissue-type and cancer-specific GEMs and their use in identifying metabolic changes occurring in response to liver disease development, stratification of the heterogeneous disease population and discovery of novel drug targets and biomarkers. We also discuss how GEMs can be integrated with other biological networks for generating more comprehensive cell/tissue models. In addition, we review the various biological network analyses that have been employed for the development of efficient treatment strategies. Finally, we present three case studies in which independent studies converged on conclusions underlying liver disease.

[1]  K. Shirabe,et al.  Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. , 2013, Molecular medicine reports.

[2]  F. Galvano,et al.  l-Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis—A Randomized and Controlled Clinical Trial , 2010, The American Journal of Gastroenterology.

[3]  Jens Nielsen,et al.  Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance. , 2016, Cell metabolism.

[4]  J. Nielsen,et al.  Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis , 2018, EBioMedicine.

[5]  A. Barabasi,et al.  Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets , 2015, Proceedings of the National Academy of Sciences.

[6]  Marcus J. Tindall,et al.  Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease , 2018, npj Systems Biology and Applications.

[7]  L. Lind,et al.  The Swedish CArdioPulmonary BioImage Study: objectives and design , 2015, Journal of internal medicine.

[8]  Feng-shang Zhu,et al.  Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. , 2008, World journal of gastroenterology.

[9]  Jason A. Papin,et al.  Functional integration of a metabolic network model and expression data without arbitrary thresholding , 2011, Bioinform..

[10]  I. de Sio,et al.  Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. , 2012, Free radical biology & medicine.

[11]  S. Piro,et al.  Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  D. Pessayre,et al.  Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. , 2002, Gastroenterology.

[13]  Avlant Nilsson,et al.  Recon3D: A Resource Enabling A Three-Dimensional View of Gene Variation in Human Metabolism , 2018, Nature Biotechnology.

[14]  Jens Nielsen,et al.  Network analyses identify liver‐specific targets for treating liver diseases , 2017, Molecular systems biology.

[15]  Roger Williams.  Hepatology through the crystal ball , 2019, Hepatology International.

[16]  Lucie Geurts,et al.  Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity , 2013, Proceedings of the National Academy of Sciences.

[17]  Masahiko Kato,et al.  Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  Jens Nielsen,et al.  Metabolic Network-Based Identification and Prioritization of Anticancer Targets Based on Expression Data in Hepatocellular Carcinoma , 2018, Front. Physiol..

[19]  K. Kharbanda,et al.  Treatment options for alcoholic and non-alcoholic fatty liver disease: A review , 2017, World journal of gastroenterology.

[20]  K. Jager,et al.  The ascending rank of chronic kidney disease in the global burden of disease study. , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  D. Moodie.  The Global Burden of Cardiovascular Disease. , 2016, Congenital heart disease.

[22]  Daniel C. Zielinski,et al.  Recon3D enables a three-dimensional view of gene variation in human metabolism , 2018 .

[23]  G. Marchesini,et al.  Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. , 2003, Gastroenterology.

[24]  M. Uhlén,et al.  Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[25]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[26]  Wei Li,et al.  HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.

[27]  J. Nielsen,et al.  Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modeling , 2014, Molecular systems biology.

[28]  N. Kaplowitz,et al.  The contribution of endoplasmic reticulum stress to liver diseases , 2011, Hepatology.

[29]  M. Uhlén,et al.  RMetD2: a tool for integration of relative transcriptomics data into Genome-scale metabolic models , 2019, bioRxiv.

[30]  I. Nookaew,et al.  Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma. , 2016, Cell reports.

[31]  Nathan D. Price,et al.  iNetModels 2.0: an interactive visualization and database of multi-omics data , 2019, bioRxiv.

[32]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[33]  Jens Nielsen,et al.  Personal model‐assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD , 2017, Molecular systems biology.

[34]  C. Bouchard,et al.  Obesity – is it a genetic disorder? , 2003, Journal of internal medicine.

[35]  Mark D. M. Leiserson,et al.  Precision Oncology: The Road Ahead. , 2017, Trends in molecular medicine.

[36]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[37]  J. Dumortier,et al.  Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. , 2012, Clinics and research in hepatology and gastroenterology.

[38]  John C. Earls,et al.  A wellness study of 108 individuals using personal, dense, dynamic data clouds , 2017, Nature Biotechnology.

[39]  Y. Rotman,et al.  Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.

[40]  Peter F Surai.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives , 2015, Antioxidants.

[41]  Jens Nielsen,et al.  An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. , 2018, Cell metabolism.

[42]  G. Bedogni,et al.  Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study , 2006, Alimentary pharmacology & therapeutics.

[43]  J. Nielsen,et al.  Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function. , 2019, Metabolic engineering.

[44]  Jens Nielsen,et al.  Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes , 2018, Proceedings of the National Academy of Sciences.

[45]  M. Wicha,et al.  Targeting Cancer Stem Cell Redox Metabolism to Enhance Therapy Responses. , 2019, Seminars in radiation oncology.

[46]  Jens Nielsen,et al.  New paradigms for metabolic modeling of human cells. , 2015, Current opinion in biotechnology.

[47]  J. Nielsen,et al.  Systems biology in hepatology: approaches and applications , 2018, Nature Reviews Gastroenterology & Hepatology.

[48]  J. Nielsen,et al.  Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization. , 2015, Cell reports.

[49]  M. Willingham,et al.  In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. , 1991, The Journal of biological chemistry.

[50]  F. Sofi,et al.  Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study , 2010, International journal of food sciences and nutrition.

[51]  Eytan Ruppin,et al.  Modeling cancer metabolism on a genome scale , 2015, Molecular systems biology.

[52]  R. Vettor,et al.  Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? , 2018, Antioxidants.

[53]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[54]  H. Kume,et al.  Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers , 2019, bioRxiv.

[55]  Miha Mraz,et al.  Computational modelling of genome-scale metabolic networks and its application to CHO cell cultures , 2017, Comput. Biol. Medicine.

[56]  Jens Nielsen,et al.  Elucidating the interactions between the human gut microbiota and its host through metabolic modeling , 2014, Front. Genet..

[57]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[58]  V. Hatzimanikatis,et al.  Investigating the deregulation of metabolic tasks via Minimum Network Enrichment Analysis (MiNEA) as applied to nonalcoholic fatty liver disease using mouse and human omics data , 2018, bioRxiv.

[59]  T. Jacks,et al.  PKM2, cancer metabolism, and the road ahead , 2016, EMBO reports.

[60]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[61]  Songfang Wu,et al.  Dual roles of PKM2 in cancer metabolism. , 2013, Acta biochimica et biophysica Sinica.

[62]  T. Zeng,et al.  Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. , 2013, Biochemical and biophysical research communications.

[63]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[64]  Jens Nielsen,et al.  The gut microbiota modulates host amino acid and glutathione metabolism in mice , 2015 .

[65]  Cheng Zhang,et al.  TCSBN: a database of tissue and cancer specific biological networks , 2017, Nucleic Acids Res..

[66]  Patricio Rojas-Silva,et al.  Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet–Induced Metabolic Syndrome , 2015, Diabetes.

[67]  Chunping Jiang,et al.  The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma , 2014, BioMed research international.

[68]  Jason A. Papin,et al.  TIGER: Toolbox for integrating genome-scale metabolic models, expression data, and transcriptional regulatory networks , 2011, BMC Systems Biology.

[69]  J. Borén,et al.  The Potential Use of Metabolic Cofactors in Treatment of NAFLD , 2019, Nutrients.

[70]  M. Laakso,et al.  Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease. , 2017, Cell metabolism.

[71]  A. Mardinoğlu,et al.  Systems medicine and metabolic modelling , 2012, Journal of internal medicine.

[72]  Wen-Xu Wang,et al.  Exact controllability of complex networks , 2013, Nature Communications.

[73]  Yuquan Wei,et al.  Targeting Metabolic-Redox Circuits for Cancer Therapy. , 2019, Trends in biochemical sciences.

[74]  Eddy J. Bautista,et al.  Integrative Personal Omics Profiles during Periods of Weight Gain and Loss. , 2018, Cell systems.

[75]  William J. Israelsen,et al.  Pyruvate kinase: Function, regulation and role in cancer. , 2015, Seminars in cell & developmental biology.

[76]  M. Khoshbaten,et al.  N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease , 2010, Hepatitis monthly.

[77]  F. Bäckhed,et al.  The gut microbiota and metabolic disease: current understanding and future perspectives , 2016, Journal of internal medicine.

[78]  K. Faber,et al.  Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD) , 2017, Nutrients.